FAKTA 2006 Pharmaceutical market and healthcare

1
FAKTA 2006Pharmaceutical marketand healthcare
2
Pharmaceutical sales in Sweden 1980-2005Pharmacy
purchasing price (AIP), MSEK incl. vet. excl.
extempore
Year
Total
Year
Total
1980 1985 1990 1995 1996 1997 1998
2 445 4 189 7 053 13 393 15 808 14 263 16 572
1999 2000 2001 2002 2003 2004 2005
18 421 20 259 21 647 23 252 23 689 24 237 25 284
Source LIF, IMS Health
3
Pharmaceutical sales in Sweden 1980-2005Pharmacy
purchasing price (AIP), MSEK incl. vet. excl.
extempore
MSEK
Year
Source LIF, IMS Health
4
Number of prescribed items 2000-2005 (Human drugs)
Million items
Year
Source Apoteket AB
5
Pharmaceutical sales of Apoteket AB 1980-2005
Pharmacy prices (AUP), incl. vet.
Year
Total
Hospital
To the public

Prescribed
OTC
MSEK
MSEK
MSEK


MSEK

1980 1985 1990 1995 2000 2001 2002 2003 2004 2005
3619 5860 10050 17388 25069 26665 28489 28341 2917
4 30033
604 1021 1615 2100 3346 3520 3503 2890 3459 4078
17 18 16 12 13 13 12 10 12 14
2696 4287 7606 13802 19862 21126 22793 23175 23300
23358
74 73 76 79 79 79 80 82 80 77
319 552 829 1487 1861 2019 2193 2278 2415 2596
9 9 8 9 7 7 8 8 8 9

Excl. VAT

Includes requisitions for hospital care

Source Apoteket AB
6
Per capita sales of pharmaceuticals
2000-2005Pharmacy prices (AUP), VAT excl.Human
drugs
SEK
Year
Source Apoteket AB
7
Commodity group Percentage share of total
consumption per household in Sweden 2004
Insurance Tobacco Wine, spirits and beer Health
Care Communication Clothing and
shoes Food Recreation and culture Housing
1,2 1,6 2,0 2,6 3,1 5,0 10,6 11,4 27,6
Housing, water, electricity, gas and other fuel
Source SCB
8
Parallel imported pharmaceuticalsinto Sweden
(AIP)
Share of total market
Import value MSEK
Year
1997 1998 1999 2000 2001 2002 2003 2004 2005
269 1007 1396 1749 2011 2085 2099 2525 3016
1,9 6,1 7,6 8,6 9,3 9,0 8,9
10,4 11,9
Source LIF, IMS Health
9
The cost increase components in pharmaceutical
sales in Sweden 1995-2005 Pharmacy purchasing
prices (AIP), incl. vet.
Sales increase
Price changes
Volume changes
Switch
Year
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
2005
12,8 17,9 -9,6 16,9 11,3 9,9 6,6 8,0 3,0 1,7 4,0
2,5 1,4 0,7 0,3 0,4 0,03 -0,3 -0,02 -2,7 -1,3 -0,4
4,1 8,8 -13,7 10,5 5,1 2,3 4,0 3,2 1,0 1,5 2,4
5,7 6,9 4,0 5,5 5,5 7,4 2,8 4,6 4,8 1,5 2,0
Source Apoteket AB
10
Sales of the 15 largest pharmaceutical products
in Sweden 2005Pharmacy purchasing prices (AIP),
MSEK
The 15 largest products accounted for 16 of
total sales in 2005 incl vet.
Enbrel
Immunosuppressive
373
Anti-asthmatic
339
Symbicort
Cholesterol triglyc-red
Lipitor
323
Anti-depressant
321
Zoloft
Immunosuppressive agent
299
Remicade
Antagon, plain
Cozaar
281
Zyprexa
270
Neuroleptic
Efexor
261
Anti-depressant
Beta blocking agent
Seloken
261
Omeprazol
231
Proton pump inhibitor
Anti-asthmatic
228
Seretide
Neorecormon
223
Anti-anaemics
Lanzo
217
Proton pump inhibitor
Anti-asthmatic
Pulmicort
217
208
Genotropin
Growth hormone
Non-branded generics
Source LIF, IMS Health
11
Sales in Sweden by the 15 largest pharmaceutical
manufacturing companies 2005Sales in MSEK at
pharmacy purchasing prices (AIP), incl. agency
sales and vet.
Pfizer
3272
3056
AstraZeneca
GlaxoSmithKline
1345
992
Novartis
922
Wyeth
891
MSD
Roche
872
697
Novo Nordisk
Janssen-Cilag
623
571
Aventis Pharma
537
Lilly
Baxter
525
520
Abbott
Schering-Plough
443
420
Boehringer Ingelheim
Source LIF, IMS Health
12
Pharmaceutical sales 2005, excluding veterinary
products, by main area of use according to the
anatomical therapeutic chemical classification
system (ATC)Pharmacy purchasing prices (AIP),
MSEK
1990
2005
1980
MSEK


MSEK

MSEK
ATC
Central nervous system (N) Antineoplastic and
immuno-modulating agents (L) Alimentary tract
and metabolism (A) Cardiovascular system
(C) Blood and blood forming organs
(B) Respiratory system (R) General
antiinfectives, systemic (J) Genito urinary
system and sex hormones (G) Musculo-skeletal
system (M) Systemic hormonal preparations, excl
sex hormones and insulines (H) Dermatologicals
(D) Sensory organs Others (P och V) Total
367 430 442 213 228 208 97 147 87 46 146 2411
15,2 17,8 18,3 8,8 9,5 8,6 4,0 6,1 3,6 1,9 6,2
100
863 1054 1084 695 803 705 282 314 237 173 672 6
882
12,5 15,3 15,7 10,1 11,7 10,2 4,1 4,6 3,4 2,5 9
,8 100
4850 3452 2844 2737 2336 1994 1950 1308 1035 699
618 434 553 24809
19,5 13,9 11,5 11,0 9,4 8,0 7,9 5,3 4,2 2,8 2,5 1
,7 2,2 100
1980 and 1990 included in Others (P)
Antiparasitic products, (V) Various
Source LIF, IMS Health
13
Pharmaceutical sales 2005, excluding veterinary
products, of the ten largest groups on the second
level according to the anatomical therapeutic
chemical classification system (ATC)Pharmacy
purchasing prices (AIP), MSEK
MSEK
1399
Psychoanaleptics
1359
Antiasthmatics
1156
Analgesics
1153
Immunosuppressive agents
1087
Antineoplastic agents
945
Drugs for acid related disorders
Psycholeptics
915
823
Drugs used in diabetes
ACE inhibitors
804
Antibacterials forsystematic use
730
Source IMS Health
14
Pharmaceutical sales 20002005, divided in
generics and human market
MSEK
Source LIF, IMS Health
15
Pharmaceutical sales 20002005, divided in
generics and human market (AIP), DDD
MSEK
Excl. ATC code D, Dermatologicals, and B05,
Blood substitutes and perfusion solutions
Source IMS Health
16
The number of approved medicinal products in
Sweden on January 1st each year
Number
Source Läkemedelsverket
17
National cases submitted in Sweden 1997-2005
Note According to the definition by the Medical
Products Agency, a case includes all applications
with the same product name submitted and
evaluated at the same time.
Source Läkemedelsverket
18
Finalized national cases in Sweden during
1997-2005
Note According to the definition by the Medical
Products Agency, a case includes all applications
with the same product name submitted and
evaluated at the same time.
Source Läkemedelsverket
19
The number of NCE approved inthe central and
national procedure 19962005, human drugs
Antal läkemedel
Source Läkemedelsverket
20
Total processing time for approval of
applications for marketing authorisations of
medicinal products 1995-2005Excludes medicinal
products approved in the centralised procedure
Processing time in months
Mean value
No. of approved medicinal products
Median
Range
Year
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
2005
293 232 343 507 641 611 475 635 810 1115 914
12 12 10 10 11 10 12 10 10 10 12
10 10 8 8 10 - 10 8 7 7 8
1-46 1-40 1-48 1-42 1-41 0-54 0-46 1-70 1-78 1-92
1-98
The total processing time includes both the
active evaluation time and the clock stop.
Source Läkemedelsverket
21
Total processing time for approval of new
chemical entities (NCEs) 1995-2005Excludes NCE
approved in the centralised procedure
Processing time in months
Mean value
Median
Range
Number of NCEs
Year
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
2005
53 35 33 31 35 35 32 29 14 25 12
15 12 12 13 13 14 13 16 9 13 19
14 12 7 13 10 - 10 7 6 9 11
4-37 4-26 4-26 4-29 4-37 1-54 1-46 3-70 1-24 3-36
5-98
The total processing time excludes both the
active evaluation time and the clock stop.
Source Läkemedelsverket
22
Swedens import and export of pharmaceuticals and
balance of trade 1980-2005SITC 542
Balance of trade
Year
MSEK
MSEK
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
2000 2001 2002 2003 2004 2005
3 583 5 843 7 221 10 902 12 123 10
297 11 475 14 764 18 796 21 740 24
199 28 282 26 814 35 143 32 207 31 979
Export
Import
Source SCB
23
Pharmaceutical trade balance in Sweden 19902005
90 91 92 93 94 95 96 97 98 99 00 01 02 03 04 05
3583 5843 7221 10902 12123 10297 11475 14764 18796
21740 24199 28282 26814 35143 32207 31979
MSEK
Year
Source SCB
24
Swedens export of pharmaceuticals by country 2005
Source SCB
25
Swedens import of pharmaceuticlas by country 2005
Total import 14594 MSEK
Source SCB
26
AstraZeneca / Certain key figures 2005
Total sales Share pharmaceuticals
RD costs of total turnover
190315 MSEK 97 18
Total pharmaceutical sales Abroad
In Sweden
185174 MSEK 98,7 1,3
Total RD costs Whereof in Sweden
Share/Sweden
26851 MSEK 11583 MSEK 43
Capital investments (net) Whereof in Sweden
Share/Sweden
6436 MSEK 1716 MSEK 27
Totalt number of employees In Sverige
Share/Sweden
64900 12223 19
Emloyees within RD Whereof in Sweden
Share
12190 4958 41
Anm The figures are converted from USD into SEK.
The figures for Sweden are preliminary.
1 USD 7,94635 SEK
Source AstraZeneca
27
AstraZeneca / Certain key figures 2005
RD costs of total turnover
Total sales
Share pharmaceuticals
190315 MSEK 97 18
Abroad
In Sweden
Total pharmaceutical sales
185174 MSEK 98,7 1,3
Total RD costs Whereof in Sweden
Share/Sweden
26851 MSEK 11583 MSEK 43
Note The figures are converted from USD into
SEK. The figures for Sweden are preliminary.
1 USD 7,94635 SEK
Source AstraZeneca
28
AstraZeneca / Certain key figures 2005
Whereof in Sweden
Capital investments (net)
Share/Sweden
6436 MSEK 1716 MSEK 27
In Sweden
Share/Sweden
Total number of emloyees
64900 MSEK 12223 19
Emloyees within RD Whereof in Sweden Share
12190 4958 41
Note The figures are converted from USD into
SEK. The figures for Sweden are preliminary.
1 USD 7,94635 SEK
Source AstraZeneca
29
RD clinical costs in Sweden19992005
Costs (billion SEK)
5,0
4,5
4,3
4,1
4,0
3,9
3,6
Year
Source LIF inquiry to member companies
30
Started clinical trials in Sweden 20012005
Year
Number of protocols
Source LIF inquiry to member companies
31
Started clinical trials in Sweden 20012005
Year
Source LIF inquiry to member companies
32
Current costs and capital investments for RD in
certain Swedish branches of manufacturing 2003,
SEK
Investment expenditures
RD, Total
Current costs
Branch
Telecommunication equipment, optic
products Transport equipment Pharmaceuticals Non-e
lectrical machinery Chemical Industry
excl. pharmaceuticals Pulp and paper
products Food products
17 883 14 588 11 751 5 766 1 446 983 351
201 905 1 383 266 66 76 59
18 084 15 493 13 134 6 032 1 512 1 059 410
Source SCB
33
Total person-years for RD and person-years
performed by postgraduates in certain industry
sectors 2003
Whereof postgraduates
Total
Industry sector
Share
Pharmaceutical Paper pulp Food
products Telecommunication equipment optic
products Machinery Transport equipment
5053 849 344 11993 4789 11479
1284 79 29 731 185 410
25 9 8 6 4 4
Source SCB
34
Net price index and pharmaceutical price index
1980-2005Consumer price index excl. VAT Net
price indexAIP pharmacy purchasing price
Index 1980 100
NPI
AIP
Year
Source SCB, Apoteket AB
35
AUP, AIP and DIP
AUP Pharmacy retail price
16
AIP Pharmacy purchasing price
2-3
DIP Wholesalers purchasing price (ex-manufactur
ing price)
Estimated figure Residual
) )
81-82
Note The figures are averages for sales of
prescribed pharmaceuticals in open care.
Source Apoteket AB, LIF
36
Pharmaceutical sales in Sweden by
non-prescription and prescription only, incl. vet.
MSEK
Year
Source LIF, IMS Health
37
Pharmaceutical sales in Sweden 20002005 total
market, non-prescription and prescription only
Per cent
Source LIF, IMS Health
38
Total non-prescription market growth compared to
the growth of the ATC code N07B A (Drugs used in
nicotine dependence), 20002005
Per cent
Source LIF, IMS Health
39
Prescription free pharmaceutical sales
20002005 divided in ATC code N07B A (drugs
used in nicotine dependence) and other
non-prescription sales
MSEK
Year
Source LIF, IMS Health